Abbott Laboratories's Stock Analysis

Abbott Laboratories Approves New Incentive Stock Program and Board Changes

On April 24, 2026, Abbott Laboratories appointed Kevin Conroy to its Board of Directors and shareholders approved the 2026 Incentive Stock Program. This program, which replaces the 2017 Incentive Stock Program, allows for the issuance of various equity-related awards to non-employee directors and employees, with a maximum of 140 million common shares available for issuance, subject to certain adjustments. The 2026 Program will be administered by the Compensation Committee and has a term of ten years.

Additionally, Abbott's Board of Directors amended its by-laws to increase the number of board members from twelve to thirteen, effective the same day. The Annual Meeting of Shareholders held on April 24, 2026, included voting on these matters among others, reflecting significant governance and compensation structure changes within the company.

Apr 27, 2026 16:06:40

Abbott Laboratories Faces Settlement in Shareholder Derivative Lawsuit

Abbott Laboratories is currently involved in a consolidated shareholder derivative litigation concerning allegations against certain current and former directors and officers for breaches of fiduciary duty and violations of federal securities laws. The court has preliminarily approved a proposed settlement that, if finalized, would dismiss all claims against the defendants and implement governance reforms aimed at enhancing Abbott’s internal reporting and oversight. A final settlement hearing is scheduled for June 4, 2026, where the court will evaluate the fairness of the settlement and any objections from shareholders.

The proposed settlement includes a potential attorneys' fee request of up to $15.85 million, which is subject to court approval. Shareholders are encouraged to review the details of the settlement and can submit objections or participate in the hearing if they wish. The settlement aims to resolve ongoing litigation while providing material benefits to Abbott and its shareholders by improving corporate governance practices.

Apr 17, 2026 16:04:06

Abbott Laboratories Reports First Quarter 2026 Financial Results

Abbott Laboratories announced its first-quarter 2026 financial results, reporting a GAAP diluted earnings per share (EPS) of $0.61 and an adjusted diluted EPS of $1.15, marking a 6% growth. The company achieved a 7.8% increase in reported sales and a 3.7% increase in comparable sales. The acquisition of Exact Sciences, completed on March 23, 2026, positions Abbott as a leader in the oncology diagnostics market, contributing to overall growth. Abbott projects comparable sales growth for the full year of 6.5% to 7.5% and adjusted diluted EPS between $5.38 and $5.58, factoring in dilution from the acquisition.

In its business segments, Abbott reported a 6.1% increase in diagnostics sales, supported by the performance of its cancer diagnostics following the Exact Sciences acquisition. Established pharmaceuticals sales rose by 13.2%, while medical devices sales increased by 13.2% as well, driven by strong demand in various product lines. However, worldwide nutrition sales declined by 6.0%, attributed to lower volumes and strategic pricing actions. Abbott also declared its 409th consecutive quarterly dividend of $0.63 per share, reflecting its long-standing commitment to returning value to shareholders.

Apr 16, 2026 07:36:25

Abbott Completes Acquisition of Exact Sciences Corporation

On March 23, 2026, Abbott Laboratories finalized its acquisition of Exact Sciences Corporation, making it a wholly owned subsidiary. As part of the merger agreement, shareholders of Exact Sciences received $105.00 per share in cash. This acquisition enhances Abbott’s capabilities in the cancer screening and diagnostics market, which is rapidly growing due to increasing global cancer incidence.

The merger positions Abbott to expand its offerings in preventative and personalized cancer care, adding key products such as the Cologuard® test and Oncotype DX®. The acquisition is expected to contribute to Abbott's growth strategy in the $60 billion U.S. cancer screening and precision oncology diagnostics sectors, with a comprehensive pipeline aimed at early cancer detection and treatment optimization.

Mar 23, 2026 08:54:17

Abbott Laboratories Issues $20 Billion in Senior Notes

On March 9, 2026, Abbott Laboratories completed a public offering of $20 billion in senior notes, which includes various series of notes with differing interest rates and maturities ranging from 2029 to 2066. The proceeds from this offering are intended to finance the acquisition of Exact Sciences Corporation, repay certain debts of Exact Sciences, cover related fees and expenses, and for general corporate purposes. If the acquisition is not completed by a specified date, Abbott is required to redeem the outstanding notes at a premium.

The notes were sold under a pricing agreement with several financial institutions, and the offering was registered with the Securities and Exchange Commission. The summary provided does not encompass all details related to the notes and interested parties are encouraged to refer to the Prospectus Supplement and related documents for comprehensive information regarding the terms and conditions of the offering.

Mar 09, 2026 16:21:32

Abbott Laboratories Announces $20 Billion Senior Notes Offering

Abbott Laboratories has entered into a pricing agreement to issue $20 billion in senior notes, which includes various floating and fixed-rate notes with maturities ranging from 2029 to 2066. The offering is set to close on March 9, 2026, and the notes will be sold under a prospectus supplement filed with the SEC.

The net proceeds from this offering will be used primarily to finance the acquisition of Exact Sciences Corporation, pay off Exact Sciences' existing debts, cover related fees and expenses, and for general corporate purposes. Abbott has included customary representations, warranties, and covenants in the pricing agreement, and it will also indemnify the underwriters against certain liabilities related to the offering.

Feb 26, 2026 16:16:53

Abbott Laboratories Board Size Reduced to Twelve Members

Abbott Laboratories' Board of Directors has amended its By-Laws to reduce the number of board members from thirteen to twelve. This change will take effect on April 24, 2026. The amendment was made on February 20, 2026, as part of a restructuring of the board's composition.

Feb 20, 2026 16:17:51

Abbott Laboratories Reports Q4 and Full-Year 2025 Results

Abbott Laboratories announced its financial results for the fourth quarter and full year of 2025, reporting a fourth-quarter GAAP diluted EPS of $1.01 and an adjusted diluted EPS of $1.50, reflecting a 12% growth. For the full year, the company reported GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, marking a 10% growth. Fourth-quarter sales increased by 4.4% on a reported basis, with full-year sales reaching $44.3 billion, an increase of 5.7%. Abbott's management highlighted the exclusion of COVID-19 testing sales from organic growth metrics to better reflect core business performance.

Looking ahead, Abbott projects full-year 2026 organic sales growth between 6.5% and 7.5%, with adjusted diluted EPS anticipated to be between $5.55 and $5.80. The company also announced an agreement to acquire Exact Sciences to strengthen its position in the cancer diagnostics market, expected to close in the second quarter of 2026. Additionally, Abbott declared a quarterly dividend of $0.63 per share, marking the 408th consecutive dividend payment, and underscoring its commitment to returning value to shareholders.

Jan 22, 2026 07:35:32

Abbott Laboratories Expands Board of Directors to Thirteen Members

Abbott Laboratories has appointed Nita Ahuja, M.D. to its Board of Directors, increasing the board size from twelve to thirteen members, effective December 12, 2025. This change reflects the company’s ongoing commitment to enhancing its governance and oversight capabilities.

The company’s by-laws were also amended to outline the processes for shareholder nominations and proposals during annual meetings. Shareholders must adhere to specific notice requirements to propose business or nominate directors, ensuring that the board maintains control over the nomination process and that all shareholder actions are properly documented.

Dec 12, 2025 16:10:48

Abbott Laboratories Announces Blackout Period for Retirement Plans

Abbott Laboratories has announced a Blackout Period affecting its Stock Retirement Plans due to administrative changes, including new recordkeepers and trustees. This period will begin on December 24, 2025, and is expected to end during the week of January 11, 2026. During this time, participants will be unable to make any transactions involving their Plan accounts, including changing contribution rates or diversifying investments in Abbott common shares.

Additionally, directors and executive officers will face trading restrictions on Abbott securities during the Blackout Period, as mandated by the Sarbanes-Oxley Act and Regulation BTR. These restrictions will apply from December 15, 2025, until after the fourth quarter earnings release, and will remain in effect even if the general insider trading policy is lifted. Interested parties can obtain more information about the Blackout Period by contacting Abbott Laboratories directly.

Nov 21, 2025 16:06:09